Adaptive approaches to licensing represent an important evolutionary path for drug development, regulation, and learning that can benefit all parties – patients, payers, providers, regulators and drug developers. They may also significantly improve both patient outcomes and the timeline and cost of bringing a new drug to market. But they will also require unprecedented cooperation among various stakeholders. Learn how an international consortium is making great strides – sparking dialogue around adaptive licensing approaches, defining a workable toolkit and collaborative partnerships, and evaluating drug programs with the potential to establish the first international pilot in 2013.
- Explain the concept of adaptive approaches to licensing and what it aims to achieve
- Review the work of an international consortium exploring adaptive approaches to licensing
- Discuss opportunities and challenges to implementation of adaptive approaches to licensing
Ability Level: Intermediate
Session ID: 1927